Get the Stockscreener App
8.00
0.38%
0.02
After Hours:
7.90
-0.10
-1.25%
Tango Therapeutics Inc stock is traded at $8.00, with a volume of 1.49M.
It is up +0.38% in the last 24 hours and down -11.29% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$7.98
Open:
$7.77
24h Volume:
1.49M
Relative Volume:
0.52
Market Cap:
$1.07B
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-6.015
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
-4.41%
1M Performance:
-11.29%
6M Performance:
+434.02%
1Y Performance:
+122.51%
1-Day Range:
$7.69
$8.10
1-Week Range:
$7.49
$8.74
52-Week Range:
$1.03
$9.70
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
8.005 | 1.07B | 24.30M | -145.57M | -149.17M | -1.33 |
|
ARGX
Argen X Se Adr
|
918.60 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.51 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.80 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.87 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
B. Riley Adjusts Price Target on Tango Therapeutics to $14 From $8, Maintains Buy Rating - MarketScreener
Will Tango Therapeutics Inc. stock benefit from automation2025 Valuation Update & Safe Capital Growth Tips - newser.com
Why Tango Therapeutics Inc. stock remains on watchlistsJuly 2025 Gainers & Technical Entry and Exit Tips - newser.com
Will Tango Therapeutics Inc. stock maintain dividend yieldInsider Selling & Reliable Breakout Forecasts - newser.com
Using AI based signals to follow Tango Therapeutics Inc.2025 Macro Impact & Short-Term High Return Strategies - newser.com
Does Tango Therapeutics Inc. fit your quant trading modelMarket Growth Report & Daily Market Momentum Tracking - newser.com
Long term hold vs stop loss in Tango Therapeutics Inc.July 2025 Trade Ideas & Daily Risk Controlled Trade Plans - newser.com
Why Tango Therapeutics Inc. is moving today2025 Fundamental Recap & Daily Stock Momentum Reports - newser.com
Can Tango Therapeutics Inc. stock outperform in 2025 bull marketWeekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
How Tango Therapeutics Inc. stock performs in rising dollar environment2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Short interest data insights for Tango Therapeutics Inc.July 2025 PostEarnings & Safe Entry Zone Tips - newser.com
Why Tango Therapeutics Inc. stock is trending among retail tradersWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Will Tango Therapeutics Inc. stock attract ESG investorsMarket Rally & Daily Profit Maximizing Trade Tips - newser.com
Tango Therapeutics (TNGX): Evaluating Valuation Following Strong Revenue Growth and Doubling Share Price - Yahoo Finance
How Investors May Respond To Tango Therapeutics (TNGX) Posting First Profit on Surging Q3 Revenue - Yahoo Finance
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet - MSN
How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Momentum & Free Fast Entry Momentum Trade Alerts - newser.com
How strong is Tango Therapeutics Inc. stock balance sheet2025 Biggest Moves & Weekly Stock Performance Updates - fcp.pa.gov.br
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.12%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):